|
Gene: CHRM2 |
Gene summary for CHRM2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CHRM2 | Gene ID | 1129 |
Gene name | cholinergic receptor muscarinic 2 | |
Gene Alias | HM2 | |
Cytomap | 7q33 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A4D1Q0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1129 | CHRM2 | A015-C-203 | Human | Colorectum | FAP | 1.41e-06 | 5.50e-01 | -0.1294 |
1129 | CHRM2 | A002-C-116 | Human | Colorectum | FAP | 2.18e-13 | 6.14e-01 | -0.0452 |
1129 | CHRM2 | CRC-3-11773 | Human | Colorectum | CRC | 5.06e-08 | 5.79e-01 | 0.2564 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00902574 | Colorectum | FAP | regulation of muscle system process | 58/2622 | 252/18723 | 7.22e-05 | 1.33e-03 | 58 |
GO:00030122 | Colorectum | FAP | muscle system process | 89/2622 | 452/18723 | 4.63e-04 | 5.39e-03 | 89 |
GO:00069371 | Colorectum | FAP | regulation of muscle contraction | 37/2622 | 169/18723 | 3.39e-03 | 2.47e-02 | 37 |
GO:00902575 | Colorectum | CRC | regulation of muscle system process | 51/2078 | 252/18723 | 1.49e-05 | 4.63e-04 | 51 |
GO:00030123 | Colorectum | CRC | muscle system process | 74/2078 | 452/18723 | 3.92e-04 | 5.80e-03 | 74 |
GO:00069372 | Colorectum | CRC | regulation of muscle contraction | 33/2078 | 169/18723 | 8.65e-04 | 1.07e-02 | 33 |
GO:1903522 | Colorectum | CRC | regulation of blood circulation | 43/2078 | 256/18723 | 3.70e-03 | 3.12e-02 | 43 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa048106 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
hsa04024 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa048107 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
hsa040241 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa048108 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
hsa040242 | Colorectum | CRC | cAMP signaling pathway | 47/1091 | 225/8465 | 4.57e-04 | 4.77e-03 | 3.23e-03 | 47 |
hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
hsa047252 | Colorectum | CRC | Cholinergic synapse | 24/1091 | 113/8465 | 8.58e-03 | 3.98e-02 | 2.70e-02 | 24 |
hsa048109 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
hsa040243 | Colorectum | CRC | cAMP signaling pathway | 47/1091 | 225/8465 | 4.57e-04 | 4.77e-03 | 3.23e-03 | 47 |
hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
hsa047253 | Colorectum | CRC | Cholinergic synapse | 24/1091 | 113/8465 | 8.58e-03 | 3.98e-02 | 2.70e-02 | 24 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHRM2 | deletion | Frame_Shift_Del | c.360delC | p.Asp120GlufsTer10 | p.D120Efs*10 | P08172 | protein_coding | TCGA-97-8172-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
CHRM2 | deletion | In_Frame_Del | novel | c.838_840delAAG | p.Lys280del | p.K280del | P08172 | protein_coding | TCGA-39-5036-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
CHRM2 | SNV | Missense_Mutation | novel | c.189C>G | p.Phe63Leu | p.F63L | P08172 | protein_coding | tolerated(1) | benign(0.105) | TCGA-CR-7388-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
CHRM2 | SNV | Missense_Mutation | novel | c.1042G>T | p.Gly348Trp | p.G348W | P08172 | protein_coding | deleterious(0.02) | possibly_damaging(0.886) | TCGA-CV-7102-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHRM2 | SNV | Missense_Mutation | c.952N>A | p.Glu318Lys | p.E318K | P08172 | protein_coding | tolerated(0.78) | benign(0.012) | TCGA-CV-7432-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CHRM2 | SNV | Missense_Mutation | novel | c.888G>C | p.Met296Ile | p.M296I | P08172 | protein_coding | tolerated(0.21) | benign(0) | TCGA-CV-7440-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CHRM2 | SNV | Missense_Mutation | c.49N>T | p.Pro17Ser | p.P17S | P08172 | protein_coding | tolerated(0.1) | probably_damaging(1) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CHRM2 | SNV | Missense_Mutation | novel | c.238N>C | p.Tyr80His | p.Y80H | P08172 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-2A-A8W3-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
CHRM2 | SNV | Missense_Mutation | c.781N>G | p.Gln261Glu | p.Q261E | P08172 | protein_coding | tolerated(0.65) | benign(0.105) | TCGA-XA-A8JR-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD | |
CHRM2 | SNV | Missense_Mutation | c.1018A>G | p.Thr340Ala | p.T340A | P08172 | protein_coding | tolerated(0.59) | benign(0.003) | TCGA-BR-4366-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | DOXACURIUM | DOXACURIUM | ||
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135652307 | ||
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | ROCURONIUM | ROCURONIUM | ||
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | allosteric modulator | 135650308 | ||
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135650349 | HEXOCYCLIUM | |
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | allosteric modulator | 135652717 | STAUROSPORINE | |
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 223365885 | DOTHIEPIN | |
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135650527 | ||
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | allosteric modulator | 135651147 | ||
1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135650178 | DICYCLOMINE |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |